Study of Olverembatinib (HQP1351) in Patients With CML-CP
A phase 3 trial of Olverembatinib run by Ascentage Pharma Group Inc., now recruiting.
Overview
Study of Olverembatinib (HQP1351) in Patients With CML-CP is a phase 3 interventional study registered as NCT06423911 by Ascentage Pharma Group Inc., with 333 participants planned, started 2024-02-05. Conditions listed: Chronic Myeloid Leukemia, CML, CML, Chronic Phase. No results are recorded here; the registry entry is the source.
Setting
A Global, Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML-CP)
Phase
Phase 3
Sponsor
Ascentage Pharma Group Inc.
Registry
Enrolled
333
Similar pages
not linked directly; found by shared links- TrialA Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
Shares Olverembatinib, Ascentage Pharma.
- TrialA Study of Olverembatinib in SDH-deficient GIST.
Shares Olverembatinib, Ascentage Pharma.
- TrialStudy of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Shares Olverembatinib, Ascentage Pharma.
- TargetBCR::ABL1 (Philadelphia chromosome)
Shares Olverembatinib, Ascentage Pharma.
- CancerChronic myeloid leukaemia (CML)
Shares Olverembatinib, Ascentage Pharma.